MIL OSI Translation. Region: Germany / Deutschland –
Source: Federal Ministry for Economic Affairs and Energy Today, the guideline for federal funding of production facilities for point-of-care antigen tests comes into force, which was published yesterday in the Federal Gazette (PDF, 420 KB). The funding is intended to support companies in building up their own competitive production capacities for PoC antigen tests on a sustainable basis in Germany. Companies that invest in production capacities for suitable PoC antigen tests can apply for support from the Federal Office for Economics and Export Control (BAFA) from today. Federal Minister of Economics Peter Altmaier: “The pandemic has shown that we are more independent of sensitive products in Germany and Europe Have to make imports. This also applies to test equipment. With the new funding program, we are therefore supporting investments in order to set up competitive productions for antigen tests in Germany. In this way we contribute to the successful fight against the corona pandemic, secure added value and jobs in Germany and in the future we will be better equipped and more independent of supply chains. “Federal Minister of Health Jens Spahn:” When it comes to rapid tests, the German healthcare system must be able to rely on the domestic market. That is why we are promoting the further expansion of domestic production. This ensures the quality of the tests. And we are becoming more independent of Asian suppliers. “Funding is given to companies that have invested or have invested in new production facilities or in the expansion of existing production facilities in Germany since November 11, 2020. Funding is generally open to technology in order to provide space and incentives for the development of innovative (test) products. The companies are to receive a non-repayable grant of up to 30 percent of the eligible capital expenditure. Companies that can prove that they purchase at least 70 percent of the preliminary products, plant parts and components required for production within Germany or the European Union receive a bonus of 10 percentage points. The funding is limited to a maximum of 30 million euros per applicant. A total of up to 200 million euros is available for funding. The subsidized systems must be put into operation by December 31, 2021 at the latest and operated appropriately by June 30, 2022. Applications can be submitted from now until March 31, 2021. The funding guidelines were developed jointly by the Federal Ministry for Economic Affairs and Energy (BMWi) and the Federal Ministry of Health (BMG).
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.